A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2018
At a glance
- Drugs Rifampicin (Primary) ; Vemurafenib (Primary)
- Indications Bacterial infections; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Jul 2016 Status changed from recruiting to completed.
- 02 Nov 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 02 Nov 2015 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov.